PEAK6 Investments’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

PEAK6 Investments’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-51,100	Closed	-$5.85M	–	4396
2019 Q3	$5.85M	Sell	51,100 -14,600	-22%	-$1.45M	0.04%	598
2019 Q2	$6.26M	Buy	65,700 +19,900	+43%	+$1.87M	0.04%	573
2019 Q1	$4.18M	Buy	+45,800	New	+$3.75M	0.02%	805

Other funds holding CBPO

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MCP

Maso Capital Partners Hong Kong $60.9M AUM 0.38% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PEAK6 Investments's CBPO Position: Q1 2019 in Review

PEAK6 Investments sold out of China Biologic Products Holdings, Inc. (CBPO) in Q1 2019, closing a stake of 8,125 shares — an estimated $665K sold.

PEAK6 Investments first reported a position in CBPO in Q4 2018 and held it in 1 quarter. The position peaked at $617K in Q4 2018. 69 funds tracked by Wall St. Rank hold CBPO as of Q1 2019.

PEAK6 Investments reported no remaining China Biologic Products Holdings, Inc. position as of Q1 2019 after selling out during the quarter.
PEAK6 Investments sold 8,125 China Biologic Products Holdings, Inc. shares in Q1 2019, an estimated $665K.
PEAK6 Investments first reported a position in China Biologic Products Holdings, Inc. in Q4 2018 and held it in 1 quarter.
PEAK6 Investments's China Biologic Products Holdings, Inc. position peaked at $617K in Q4 2018.
69 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q1 2019.

Based on PEAK6 Investments's 13F filing for Q1 2019, filed 15 May 2019.